Clinical trial
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
NCT05805956
Study timeline
Study start (actual)2022-02-15Date precision: day
Registry last updated2023-04-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Advanced Lung Cancerunresolved
Advanced Gastric Carcinomaunresolved
Advanced Cholangiocarcinomaunresolved
Interventions
IMM2902DRUG
Sponsors & collaborators
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05805956 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.